Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease

Empagliflozin (EMPA) therapy has led to improvements in patients with non-alcoholic fatty liver disease (NAFLD). Sestrin2 is a stress-inducible protein that controls the AMPK-mTOR pathway and inhibits oxidative damage in cells. This study investigated the functional implications of EMPA on the multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuting, Zhang, Guangdong, Kuang, Zenggguang, Xu, Qian, Ye, Tongtong, Li, Xue, Qu, Na, Han, Fang, Kan, Chengxia, Sun, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483033/
https://www.ncbi.nlm.nih.gov/pubmed/36133815
http://dx.doi.org/10.3389/fphar.2022.944886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483033/
https://www.ncbi.nlm.nih.gov/pubmed/36133815
http://dx.doi.org/10.3389/fphar.2022.944886

Ejemplares similares